Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.990
+0.020 (1.02%)
May 27, 2025, 3:41 PM - Market open
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Inovio Pharmaceuticals stock ranges from a low of $3.00 to a high of $18. The average analyst price target of $9.75 forecasts a 389.95% increase in the stock price over the next year.
Price Target: $9.75 (+389.95%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inovio Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $5 | Hold | Reiterates | $5 | +151.26% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +553.27% | May 14, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +151.26% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +50.75% | Mar 19, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $18 | Buy | Reiterates | $18 | +804.52% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
3.09M
from 217.76K
Increased by 1,318.56%
Revenue Next Year
18.35M
from 3.09M
Increased by 494.14%
EPS This Year
-2.33
from -3.95
EPS Next Year
-1.75
from -2.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.0M | 43.6M | 128.5M | ||
| Avg | 3.1M | 18.4M | 67.8M | ||
| Low | n/a | 9.7M | 38.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7,224.7% | 1,311.3% | 600.2% | ||
| Avg | 1,318.6% | 494.1% | 269.6% | ||
| Low | - | 214.1% | 107.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.13 | -0.63 | -0.17 | ||
| Avg | -2.33 | -1.75 | -1.10 | ||
| Low | -2.90 | -2.80 | -2.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.